{"id":"W2253719787","doi":"10.1182/blood.v122.21.1821.1821","title":"Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; University of Alberta","funders":"","keywords":"Tolerability; Medicine; Calicheamicin; Internal medicine; Rituximab; Refractory (planetary science); Gastroenterology; Regimen; Adverse effect; Neutropenia; Febrile neutropenia; Lymphoma; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009588535,0.001194641,0.001946764,0.0004046168,0.0003742319,0.0009068219,0.0009266554,0.0007951353,0.00236038],"category_scores_gemma":[0.0004675887,0.000627409,0.0009347083,0.0003461232,0.000754822,0.0006225348,0.0003741461,0.002979299,0.0007449672],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001018983,"about_ca_system_score_gemma":0.00194854,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00127061,"about_ca_topic_score_gemma":0.003238273,"domain_scores_codex":[0.9996986,0.0001205228,0.00001392483,0.000065067,0.00002691763,0.00007491416],"domain_scores_gemma":[0.9995771,0.0000429125,0.00005912737,0.00005357498,0.00003102877,0.0002363352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4675424,0.2221165,0.009051566,0.0009984048,0.001576057,0.0004717252,0.000516536,0.004252075,0.1621498,0.0005357391,0.005831482,0.1249578],"study_design_scores_gemma":[0.1912744,0.7823378,0.009420829,0.00003560147,0.000576545,0.0002478359,0.00006971586,0.001207698,0.01085229,0.0001731532,0.00378077,0.00002335668],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992821,0.001121503,0.0005640479,0.0001935846,0.00008633282,0.002835017,0.0009157087,0.0001172077,0.00134552],"genre_scores_gemma":[0.9902645,0.001271978,0.00159103,0.0003888969,0.0001030654,0.002589756,0.001643754,0.00003680996,0.002110295],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00236038,"threshold_uncertainty_score":0.007896245,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01222236660313752,"score_gpt":0.2561606938958768,"score_spread":0.2439383272927393,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}